Rare cytoplasmic mislocalization of FUS+ protein, a marker used in postmortem diagnosis of TDP-43-negative ALS/MND patients (44), was observed in 2 of the 16 (12.5%) of BMAA-dosed vervets (Fig. 3E–H). Here, FUS is linked to mild neurocognitive disorder.